Hansa Biopharma AB
OTC:HNSBF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Hansa Biopharma AB
OTC:HNSBF
|
SE |
|
FVCBankcorp Inc
F:I29
|
US |
|
ConvaTec Group PLC
LSE:CTEC
|
UK |
|
Nomura Real Estate Holdings Inc
TSE:3231
|
JP |
|
Roche Bobois SA
F:5RO
|
FR |
|
Equinor ASA
F:DNQ
|
NO |
|
C
|
Capital Bancorp Inc
F:316
|
US |
|
Paragon Care Ltd
F:PXS
|
AU |
|
N
|
Navigator Company SA
XBER:PO9
|
PT |
Wall St Price Targets
HNSBF Price Targets Summary
Hansa Biopharma AB
According to Wall Street analysts, the average 1-year price target for HNSBF is 5.84 USD with a low forecast of 2.85 USD and a high forecast of 8.46 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is HNSBF's stock price target?
Price Target
5.84
USD
According to Wall Street analysts, the average 1-year price target for HNSBF is 5.84 USD with a low forecast of 2.85 USD and a high forecast of 8.46 USD.
What is the Revenue forecast for Hansa Biopharma AB?
Projected CAGR
50%
Over the last 13 years, the compound annual growth rate for Revenue has been 41%. The projected CAGR for the next 8 years is 50%.
What is the Gross Profit forecast for Hansa Biopharma AB?
Projected CAGR
88%
The compound annual growth rate for Gross Profit over the next 3 years is 88%.
